anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The recommended starting dose of BALVERSA is 8 mg (two 4 mg tablets) orally once daily, with a dose increase to 9 mg (three 3 mg tablets) once daily based on tolerability, including hyperphosphatemia, at 14 to 21 days [see Dosage and Administration (2.3)]. 

Swallow tablets whole with or without food. If vomiting occurs any time after taking BALVERSA, the next dose should be taken the next day. Treatment should continue until disease progression or unacceptable toxicity occurs.

If a dose of BALVERSA is missed, it can be taken as soon as possible on the same day. Resume the regular daily dose schedule for BALVERSA the next day. Extra tablets should not be taken to make up for the missed dose.

Dose Increase based on Serum Phosphate Levels

Assess serum phosphate levels 14 to 21 days after initiating treatment. Increase the dose of BALVERSA to 9 mg once daily if serum phosphate level is < 9.0 mg/dL and there are no ocular disorders or Grade 2 or greater adverse reactions. If the phosphate level is 9.0 mg/dL or higher follow the relevant dose modifications in Table 2. Monitor phosphate levels monthly for hyperphosphatemia [see Pharmacodynamics (12.2)] .
OBJECTIVE: To investigate the effects of noninvasive brain stimulation (NIBS) on spasticity in people with multiple sclerosis (PwMS).
LITERATURE SURVEY: We searched PubMed, SCOPUS, MEDLINE, REHABDATA, PEDro, CINAHL, AMED, and Web of Science until December 2022.
METHODOLOGY: Studies were selected if they included PwMS, used transcranial direct current stimulation (tDCS) or repetitive transcranial magnetic stimulation (rTMS) as a main intervention, and were randomized controlled trials (RCTs) including at least one outcome measure evaluating spasticity. Two researchers individually screened the selected studies. The study's quality was assessed using the Cochrane Collaborations tool. The researchers decided that the meta-analysis was not possible because the treatment interventions varied among the selected studies.
SYNTHESIS: In total, 147 studies were reviewed. Of them, nine studies met the eligibility criteria and included 193 PwMS (mean age = 43.2 years), 54.4% of whom were female. Eight studies were considered "high" quality and one was considered "moderate" quality. Seven studies that used rTMS demonstrated a significant decrease in spasticity in PwMS after the intervention. The remaining studies that provided tDCS did not show meaningful effects.
CONCLUSIONS: The evidence for the influences of rTMS on spasticity in PwMS is promising. The evidence for the impact of tDCS on spasticity in PwMS was limited. Further RCTs with long-term follow-ups are encouraged.
Metformin p.o. and insulin sc After the 4 weeks run-in phase (stable metformin medication), patients will maintain on their metformin dosage (850 or 1000 mg orally twice daily) and insulin glargine (Lantus™) once daily subcutaneous will be added. Initially 2 - 4 U Lantus™ daily (depending on body weight) will be given, and adjusted every third day (telephone counseling) by adding 2 U if fasting blood glucose is not ≤ 125 mg/dl (16). After a stable dosage (i.e. no change of dosage for 1 week) has been reached, adjustments regarding an increment of Lantus™ will be based on confirmed fasting blood glucose of ≥ 126 mg/dl (on at least two consecutive day).
The invention discloses a medicine for treating the rheumatism and rheumatoid disease, belongs to the technical field of traditional Chinese medicine, and particularly relates to a medicine for arthralgia of the rheumatism and rheumatoid disease and the rheumatism and rheumatoid disease caused by wind, coldness and dampness. The rheumatism and rheumatoid disease is a common frequently-occurring disease and belongs to arthralgia according to the traditional Chinese medicine; particularly, according to the rheumatoid arthropathy, sclerotin looseness is remarkable, general osteoporosis is caused, the structure of bone is fine, the bone cortex is thin, and the density is almost equal to those of medullary spaces and surrounding tissue. Soft tissue at joints swells and fades away, muscle atrophy is caused, joint dislocation is generated, and joints are shaped like chicken feet when the disease is serious. Joint gaps are narrowed and even disappear. Fiber or bony ankylosis is caused, and labor and self-care capacity is lost. Joint redness and swelling, heat pain, dysfunction and joint deformation are clinically shown, and joint disablement is caused when the disease is serious. At present, the number of types of medicine for treating the rheumatism and rheumatoid disease is large. The pure traditional Chinese medicine preparation is manufactured with various types of pure natural plants, mineral and animals as raw materials.
Muscle weakness is associated with impaired quality of life, increased risk of falling, disability and premature mortality. Whilst ageing results in a progressive decline, even short periods of low physical activity can result in significant deterioration of muscle function and metabolic health. One such period of very low activity can occur following illness or injury. This can lead to decrease in lower limb muscle mass and strength. Muscle exercise training promotes recovery of skeletal muscles after injury though improvements vary between individuals and appear to decrease with age. Strategies to retard loss of muscle mass and function during inactivity are, thus, of critical importance in understanding of the mechanisms underlying such effects.

Vitamin K includes a group of structurally related compounds named phylloquinone (vitamin K1) and menaquinones (vitamin K2s) of which MK-4 and MK-7 are the most important. Vitamin K is an essential cofactor for gamma carboxylation, required for the effective function of a range of proteins and has been linked to chronic disease and inflammation. Muscle cell studies suggest that vitamin K2 increases expression of myogenic transcription factors such as MyoD and promotes muscle cell proliferation. There are 20 described vitamin K dependent proteins (VKDPs). It is also known that vitamin K2 inhibits the activation of NFkB independently of gamma-carboxylation. This prevents nuclear entry of NFkB and therefore, consequently, vitamin K2 inhibits NFkB to interact with its nuclear receptors. In addition, Vitamin K2 can function as an electron carrier in mitochondria, and therefore play an inhibitory role on oxidative stress and release of ROS. There is, therefore, a strong rationale for investigating the effects of vitamin K2 during ankle immobilisation. The aim of the study is to investigate the effects of vitamin K2 on skeletal muscles after ankle injury and in the recovery process.
In terms of motor development, fundamental motor skills (FMS, e.g., locomotor and object manipulation)-such as running, jumping, throwing, and kicking-are considered the essential building blocks for further, more complex gross motor movement. (24) There will be 13 FMS activities including; running, jumping, Gallop, hopping, side gliding, skipping, leaping, catching, stationary dribbles, kicking, striking a stationary ball, overarm throw and underarm throw. FMS group will receive 30 sessions for 10 weeks (3 sessions per week, 60 min per session including CPT).
PURPOSE: The composition containing the water-insoluble inhibitor for 3-hydroxy-3-methyl glutaryl CoA (HMG-CoA) is provided to increase the solubility of the inhibitor and the absorption rate of the inhibitor into the body, thereby to reduce the dosage. CONSTITUTION: The composition is prepared by adsorbing the coprecipitated and dispersed matter which is formed from 1 parts by weight of the water-insoluble inhibitor for HMG-CoA reduction enzyme and 0.1-20 parts by weight of the coprecipitation and dispersion carrier by using a volatile organic solvent, to 0.5-100 parts by weight of the adsorption carrier. The water-insoluble inhibitor for HMG-CoA reduction enzyme is preferably the lovastatin represented by the formula 1 or the simbastatin represented by the formula 2. The coprecipitation dispersion carrier is preferably selected from polyvinylpyrrolidone, Poloxamer and polyethyleneglycol. The adsorption carrier is selected from lactose, mannitol, sorbitol, sucrose, glucose, fructose and galactose. The volatile organic solvent is selected from chloroform, dichloromethane, acetone, ether, ethanol and methanol.
PATZ1-rearranged sarcomas are well-recognized tumors as part of the family of round cell sarcoma with EWSR1-non-ETS fusions. Whether PATZ1-rearranged central nervous system (CNS) tumors are a distinct tumor type is debatable. We thoroughly characterized a pediatric series of PATZ1-rearranged CNS tumors by chromosome microarray analysis (CMA), DNA methylation analysis, gene expression profiling and, when frozen tissue is available, optical genome mapping (OGM). The series consisted of 7 cases (M:F=1.3:1, 1-17 years, median 12). On MRI, the tumors were supratentorial in close relation to the lateral ventricles (intraventricular or iuxtaventricular), preferentially located in the occipital lobe. Two major histologic groups were identified: one (4 cases) with an overall glial appearance, indicated as "neuroepithelial" (NET) by analogy with the corresponding methylation class (MC); the other (3 cases) with a predominant spindle cell sarcoma morphology, indicated as "sarcomatous" (SM). A single distinct methylation cluster encompassing both groups was identified by multidimensional scaling analysis. Despite the epigenetic homogeneity, unsupervised clustering analysis of gene expression profiles revealed 2 distinct transcriptional subgroups correlating with the histologic phenotypes. Interestingly, genes implicated in epithelial-mesenchymal transition and extracellular matrix composition were enriched in the subgroup associated to the SM phenotype. The combined use of CMA and OGM enabled the identification of chromosome 22 chromothripsis in all cases suitable for the analyses, explaining the physical association of PATZ1 to EWSR1 or MN1. Six patients are currently disease-free (median follow-up 30 months, range 12-92). One patient of the SM group developed spinal metastases at 26 months from diagnosis and is currently receiving multimodal therapy (42 months). Our data suggest that PATZ1-CNS tumors are defined by chromosome 22 chromothripsis as causative of PATZ1 fusion, show peculiar MRI features (eg, relation to lateral ventricles, supratentorial frequently posterior site), and, although epigenetically homogenous, encompass 2 distinct histologic and transcriptional subgroups.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine and concerns composites for waxed reconstruction of the injured bone tissues. High-porous elastic chitosan-gelatin matrixes of porosity 90 % or more consist of chitosan and contain gelatin up to 60 wt % and sodium lauryl sulphate up to 0.2-0.4 wt %. The porous structure is produced by introducing the additives, freezing and sublimation drying. ^ EFFECT: due to elasticity and high porosity, said sponges fill bone defects with a minimum clearance that promotes the uniform formation of bone tissue throughout the defect; high solubility of matrixes provides fast bone tissue genesis. ^ 1 tbl, 1 ex
Little is known about the high risks of cognitive impairment and Alzheimer's Disease (AD) in people with type 2 diabetes. The goal of this study is to characterize brain imaging biomarkers of preclinical AD and related cognitive impairment in people with type 2 diabetes using the simultaneous EEG-fMRI approach and peripheral neuropathology biomarkers assay. We will recruit 400 patients with type 2 diabetes in the outpatient and inpatient departments. Each subject will undergo simultaneous EEG-fMRI scan, classical multimodal MRI scan, cognitive assessments and peripheral neuropathology biomarkers assay at the baseline. This study will qualify gray matter volume, cortical thickness, gray matter and white matter microstructure, cerebral blood flow, spectrum changes, as well as resting state and dynamic functional network connectivity from the imaging examination. Study duration was 3 years with a follow-up every 12 months. Cognitive assessments and imaging scan will be conducted in each follow-up visits. At the end of the study, all of the assessments will be performed again for all recruited subjects.
The invention is directed in part to a purified form of stabilized activated thrombin-activatable fibrinolysis inhibitor (TAFIa). The invention is further directed to a method of producing stabilized TAFIa. The invention is also directed to methods for therapeutic use of stabilized TAFIa such as in the treatment, prevention or management of diseases via an anti-coagulant effect. The invention is also directed to methods for therapeutic use of inhibitors of TAFIa such as in the treatment, prevention or management of diseases via a procoagulant effect. The invention is also directed to methods of diagnostic use of stabilized TAFIa such as a standard in a chromogenic or a fluorometric carboxypeptidase activity assay. The present invention is also directed to kits comprising stabilized TAFIa useful in measuring carboxypepetidase activity.
The invention relates to a high molecular weight recombinant human kallikrein and its preparation method and use. The high molecular weight recombinant human kallikrein is obtained by a mammalian cell culture production method and a specific purification method. A SDS-PAGE electrophoresis determination result shows that the high molecular weight recombinant human kallikrein is glycoprotein with molecular weight of 43-49KDa and contains 3 N-Link glycosylation binding sites respectively located at Asn78, Asn84 and Asn141. Compared with the existing human urine-derived human kallikrein, the high molecular weight recombinant human kallikrein has a complex and complete glycosylation level and obviously reduces a decarboxyamidation level. The high molecular weight recombinant human kallikrein can substantially prolong a half life in vivo and reduce side effects. The invention also relates to a research on application of the high molecular weight recombinant human kallikrein in cerebral infarction treatment.
High Fischer ratio oligopeptides (HFOs) have a variety of biological activities, but their mechanisms of action for anti-fatigue are less systematically studied at present. This study aimed to systematically evaluate the anti-fatigue efficacy of HFOs from Antarctic krill (HFOs-AK) and explore its mechanism of action through establishing the fatigue model of endurance swimming in mice. Therefore, according to the comparison with the endurance swimming model group, HFOs-AK were able to dose-dependently prolong the endurance swimming time, reduce the levels of the metabolites (lactic acid, blood urea nitrogen, and blood ammonia), increase the content of blood glucose, muscle glycogen, and liver glycogen, reduce lactate dehydrogenase and creatine kinase extravasation, and protect muscle tissue from damage in the endurance swimming mice. HFOs-AK were shown to enhance Na+-K+-ATPase and Ca2+-Mg2+-ATPase activities and increase ATP content in muscle tissue. Meanwhile, HFOs-AK also showed significantly antioxidant ability by increasing the activities of superoxide dismutase and glutathione peroxidase in the liver and decreasing the level of malondialdehyde. Further studies showed that HFOs-AK could regulate the body's energy metabolism and thus exert its anti-fatigue effects by activating the AMPK signaling pathway and up-regulating the expression of p-AMPK and PGC-α proteins. Therefore, HFOs-AK can be used as an auxiliary functional dietary molecules to exert its good anti-fatigue activity and be applied to anti-fatigue functional foods.
An AI/ML-based bioinformatics platform for encephalopathy and a medical decision improvement method are provided. The AI/ML-based bioinformatics platform includes an evidence-based clinical system and an evidence-based education system. The evidence-based clinical system includes a clinical research device and a collaborative workstation. The clinical research device can collect basic information of patients to analyze, so as to generate effective medical information. The collaborative workstation obtains interactive information between doctors and patients. The collaborative workstation establishes a pharmacovigilance based on the interactive information and the effective medical information. The evidence-based education system connects to a medical database to obtain legal medical information. The evidence-based education system establishes a real-world evidence based on the legal medical information, the effective medical information, and the interaction information, so as to selectively correct the effective medical information and the pharmacovigilance. Accordingly, the AI/ML-based bioinformatics platform and medical decision improvement method can ensure the legitimacy and correctness of medical decision-making.
Cardiac surgery related acute kidney injury (CS-AKI) is an important clinical problem. Kidney injury occurs following a cardiopulmonary bypass used during cardiac surgery procedures. The pathomechanisms of acute kidney injury (AKI) is complex and multifactorial. It may involve few injury pathways: ischemia and reperfusion, endogenous toxins, inflammation, metabolic factors and oxidative stress. Biochemical markers of acute kidney injury such as ischemia modified albumin (IMA) or urinary excreted of brush-border enzymes of the proximal renal tubules analysed perioperatively will be assessed in this study. There has been no official recommendations toward routine use of analysed biomarkers.
Subjects who had previously received the Tick borne encephalitis (TBE) primary vaccination according to conventional (C) schedule i.e., on days 0, 28 (+10) and 300 (+21) in the parent study (V48P7) and were administered 1 booster dose of Encepur adults in the first extension study, V48P7E1 (NCT00387634), were included in this group. Subjects had blood drawn annually starting from year 6 up to year 10 after booster vaccination.
Store at room temperature 20°C to 25°C (68°F to 77°F) with excursions permitted 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

Store in original unopened pouch.

Used TDS still contain some active hormones. To discard, fold the sticky sides of the TDS together, place in a sturdy container, preferably with a child-resistant cap, and place this container in the trash. Used TDS should not be flushed down the toilet. See www.fda.gov/drugdisposal for more information about disposal of medicines.
Every control subject will also realize three cardiac MRI exams if possible at the same time as the triathletes.They must be not engaged in physical activity more than 150 minutes a week on average. After each cardiac MRI, an applanation tonometry examination will aslo be performed.
To provide a design and a synthesis of a novel positively-charged prodrug of a retinoid of a general formula (31)' structure 31' or a retinoid-like compound.SOLUTION: Positively charged amino groups of these prodrugs not only remarkably increase solubility of a drug in water but also couple with negative charge in a phosphate head part group of a film. The coupling disturbs slightly the film and can generate a space for a lipophilic part of the prodrug. When the film molecule moves, a little "crack" is generated in the film for coupling of the prodrug. Thereby, the prodrug is inserted into the film. The prodrug may be medically used to remedy a state remedial with the retinoid or retinoid-like compound in human beings or animals. The prodrug may be percutaneously administered to all kinds of medical remedies and can avoid almost all side-effects of the retinoids or retinoid-like compounds.SELECTED DRAWING: Figure 2
PURPOSE: To provide a method for suppressing the proliferation of Helicobacter pylori and urease Helicobacter pylori by using a plant extract. CONSTITUTION: This method for suppressing the proliferation of the Helicobacter pylori and the urease Helicobacter pylori consists in using the aq. extract or org. extract of Thymus (or thyme). In the case of the aq. extract, at least 0.5 mg dry plant in the extract is required and about 1.2 mg or above is more preferable. The aq. extract is usable as drinks by using or without additive components or is usable in the form of a capsule or by deforming the extract to a paste.
A composition for preventing and treating obesity, which contains a N-acetylcysteine (NAC) and taurine is provided to suppress the differentiation of pre-adipocyte and adipocyte and efficiently protect the increase of adipocyte. A composition for preventing and treating obesity comprises 35-100 weight part of N-acetylcysteine and 20-50 weight part of taurine as active ingredients. The composition further comprises a pharmaceutically suitable and physiologically allowable adjuvant. The adjuvant is a solubilizing agent of solvent, disintegrant, sweetener, binder, coating flux, expander, lubricant, lubricant or flavoring agent. The composition additionally contains pharmaceutically allowable carrier. The carrier is distilled water, sterilized water, ringer solution, buffering saline, dextrose solution, maltodextrin solution, glycerol or ethanol. The composition is used in a form of diluents, dispersing agent, surfactant, binder, formulation, pill, capsule, granule, or tablet.
The invention provides compositions and methods for detecting and/or modulating TOX3 gene expression and/or biological activity. Such compositions and methods find utility in the detection and/or treatment of certain subsets of cancers, e.g. breast cancer. In particular, the inventive compositions and methods are drawn to production and use of anti-TOX3 antibodies and TOX3 nucleic acids for both detection and modulation of TOX3. The invention also provides for pharmaceutical compositions and methods for the modulation of TOX3 in a subject in need thereof. Further aspects of the invention relate to transgenic mice that either over-express or inducibly express TOX3.
The safety and effectiveness of Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution (two 4.5-ounce doses) have been established for cleansing of the colon as a preparation for colonoscopy in pediatric patients 12 years of age and older. Use of Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution in this age group is supported by evidence from an adequate and well-controlled trial of Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution in adults and a single, dose-ranging, controlled trial in 89 pediatric patients 12 years to 16 years of age [see Clinical Studies ( 14)] . In the pediatric trial, Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution (two 6-ounce doses) did not demonstrate additional treatment benefit and more patients reported gastrointestinal adverse reactions compared to Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution (two 4.5-ounce doses). Therefore, Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution (two 6-ounce doses) is not recommended for pediatric patients 12 years of age and older [see Dosage and Administration ( 2.3)] . The safety profile of Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution (two 4.5-ounce doses) in this pediatric population was similar to that seen in adults [see Adverse Reactions ( 6.1)] . 

The safety and effectiveness of Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution in pediatric patients less than 12 years of age have not been established.